Stay updated with breaking news from Coreyj Langer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Corey J. Langer, MD, FACP, discusses findings from the IMpower010 and KEYNOTE-091 studies, which examined immunotherapy in NSCLC.
Corey J. Langer, MD, outlines the prevalence of BRAF mutations in NSCLC and looked ahead to where the development pipeline of agents for the treatment of patients with BRAF-mutated NSCLC is headed.
E-Mail IMAGE: Charu Aggarwal, MD, MPH (top), Ronac Mamtani, MD, (bottom left), and Lova Sun, MD. view more Credit: Penn Medicine PHILADELPHIA--Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research from the Abramson Cancer Center at the University of Pennsylvania. In a new study published online today in JAMA Oncology, researchers show that patients harboring a KRAS gene mutation with high levels of PDL-1 lived longer when treated wi...